Literature DB >> 21964157

Electrophysiologic profile of dronedarone on the ventricular level: beneficial effect on postrepolarization refractoriness in the presence of rapid phase 3 repolarization.

Peter Milberg1, Gerrit Frommeyer, Timo Uphaus, Dennis Kaiser, Nani Osada, Günter Breithardt, Lars Eckardt.   

Abstract

BACKGROUND: Dronedarone (D) is developed to maintain sinus rhythm in patients suffering from atrial fibrillation. The aim of the present study was to investigate, whether dronedarone also has an antiarrhythmic potential in the ventricle and to elucidate the mechanisms for its low proarrhythmic potential in an experimental whole heart model. METHODS AND
RESULTS: Thirty-five rabbits underwent chronic treatment with D (n = 15; 50 mg · kg(-1) · d(-1)) and amiodarone (A; n = 20; 50 mg · kg(-1) · d(-1)). Hearts were perfused on a Langendorff apparatus. Results were compared with hearts acutely treated with sotalol (S; 50-100 μM; n = 14). A 12-lead electrocardiogram and up to 8 ventricular epi- and endocardial monophasic action potentials showed a significant prolongation of QT interval (D: +24 milliseconds, A: +28 milliseconds, S: +35 milliseconds (50 μM), +56 milliseconds (100 μM); P < 0.02) compared with baseline. In contrast to D and A, S led to a significant increase in dispersion of repolarization and exhibited reverse use dependence. D, A, and S increased refractory period, resulting in a significant increase in postrepolarization refractoriness (effective refractory period minus action potential duration; D = +12 milliseconds; A = +14 milliseconds; S = +25 milliseconds; P < 0.05). S led to a triangular action potential configuration, whereas D and A caused a fast phase 3 prolongation. After lowering of potassium concentration, 50% of S-treated hearts showed torsade de pointes, in contrast to an absence of torsade de pointes in D and A.
CONCLUSIONS: Prolongation of myocardial repolarization and postrepolarization refractoriness by D may act antiarrhythmic. A fast phase 3 repolarization in the absence of both increased dispersion of repolarization and reverse use dependence prevents proarrhythmia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21964157     DOI: 10.1097/FJC.0b013e3182377a11

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  5 in total

1.  The anti-influenza drug oseltamivir reduces atrial fibrillation in an experimental whole-heart model.

Authors:  Gerrit Frommeyer; André Mittelstedt; Julian Wolfes; Christian Ellermann; Simon Kochhäuser; Patrick Leitz; Dirk G Dechering; Lars Eckardt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-08-06       Impact factor: 3.000

2.  Verapamil as an antiarrhythmic agent in congestive heart failure: hopping from rabbit to human?

Authors:  Thom R G Stams; Vincent J A Bourgonje; Marc A Vos; Marcel A G van der Heyden
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 3.  Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms.

Authors:  Gerrit Frommeyer; Lars Eckardt
Journal:  Nat Rev Cardiol       Date:  2015-07-21       Impact factor: 32.419

4.  Electrophysiological alterations in a murine model of chronic coxsackievirus B3 myocarditis.

Authors:  Sven Kaese; Robert Larbig; Matthias Rohrbeck; Gerrit Frommeyer; Dirk Dechering; Jan Olligs; Sabine Schönhofer-Merl; Rainer Wessely; Karin Klingel; Guiscard Seebohm; Lars Eckardt
Journal:  PLoS One       Date:  2017-06-23       Impact factor: 3.240

5.  PITX2 Modulates Atrial Membrane Potential and the Antiarrhythmic Effects of Sodium-Channel Blockers.

Authors:  Fahima Syeda; Andrew P Holmes; Ting Y Yu; Samantha Tull; Stefan Michael Kuhlmann; Davor Pavlovic; Daniel Betney; Genna Riley; Jan P Kucera; Florian Jousset; Joris R de Groot; Stephan Rohr; Nigel A Brown; Larissa Fabritz; Paulus Kirchhof
Journal:  J Am Coll Cardiol       Date:  2016-10-25       Impact factor: 24.094

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.